Does MDwise Cover Eliquis? A Complete Coverage and Cost Guide

What Is MDwise and How Does Its Formulary Work?

MDwise is one of Indiana's Medicaid managed-care organizations (MCOs), operating under the Hoosier Health (Medicaid) and Hoosier Care Connect programs. Like all Indiana Medicaid MCOs, it maintains a Preferred Drug List (PDL) that determines which medications members can access, at what cost-sharing level, and whether a prior authorization step is required before the pharmacy will dispense the drug.

The Indiana Medicaid PDL Framework

Indiana's Office of Medicaid Policy and Planning (OMPP) coordinates a statewide PDL that all MCOs, including MDwise, are expected to follow as a baseline. Indiana Medicaid's pharmacy program publishes updates to the PDL quarterly. Individual MCOs can add restrictions (such as quantity limits or step therapy) on top of the state PDL, but they generally cannot remove a drug that the state has deemed covered without a valid clinical reason.

Drugs on the PDL are grouped into tiers. Preferred drugs (Tier 1 or Tier 2 on most Medicaid formularies) require no PA or a simplified PA. Non-preferred drugs require full prior authorization, meaning the prescriber must submit clinical documentation showing that preferred alternatives have been tried, are contraindicated, or are otherwise inappropriate for that specific patient. FDA labeling guidance for apixaban describes the clinical situations that prescribers routinely cite in these PA requests.

Where Eliquis Typically Falls

Across most state Medicaid PDLs, apixaban sits in a non-preferred tier relative to warfarin. Warfarin has been generic since the 1950s, costs pennies per tablet, and carries decades of monitoring data, so Medicaid programs routinely list it as the preferred oral anticoagulant. Direct oral anticoagulants (DOACs) including apixaban, rivaroxaban (Xarelto), and dabigatran (Pradaxa) are generally classified as non-preferred, meaning prior authorization is the standard hurdle a prescriber must clear before the plan will pay. CMS Medicaid pharmacy guidance supports state flexibility in managing DOAC access through PDL controls.

The Clinical Case for Apixaban: Why Prescribers Fight for It

Understanding why apixaban is worth pursuing through the PA process requires a look at its clinical track record. The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to dose-adjusted warfarin in patients with nonvalvular atrial fibrillation. ARISTOTLE, published in NEJM 2011, showed apixaban reduced the rate of stroke or systemic embolism by 21% (1.27% vs. 1.60% per year; P<0.001 for non-inferiority, P=0.01 for superiority) and cut major bleeding by 31% (2.13% vs. 3.09% per year; P<0.001).

DVT and PE: The AMPLIFY Evidence

For acute venous thromboembolism (VTE), the AMPLIFY trial (N=5,395) compared apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily for 6 months against conventional therapy (enoxaparin plus warfarin). AMPLIFY, NEJM 2013 found apixaban was non-inferior for recurrent VTE or VTE-related death (2.3% vs. 2.7%; relative risk 0.84; 95% CI 0.60 to 1.18) and caused significantly less major bleeding (0.6% vs. 1.8%; P<0.001). These outcomes directly support a PA argument that switching to warfarin exposes a specific patient to excess bleeding risk.

Renal and Hepatic Tolerability

Apixaban is eliminated approximately 27% renally, meaning it can be used cautiously in moderate chronic kidney disease where warfarin's narrow therapeutic index can be especially volatile. FDA prescribing information notes that the dose should be reduced to 2.5 mg BID when a patient meets at least two of: serum creatinine ≥1.5 mg/dL, age ≥80 years, or body weight ≤60 kg. The 2023 AHA/ACC/ACCP/HRS Atrial Fibrillation Guideline (Circulation 2023) gives DOACs a Class I recommendation over warfarin in nonvalvular AF patients eligible for oral anticoagulation.

What "Non-Preferred" Actually Means Clinically

Non-preferred status does not mean the drug is medically inferior. It means the plan requires documentation before paying. The ACC's clinical guidance on anticoagulation explicitly acknowledges that patient-specific factors, including labile INR on warfarin, renal function, fall risk, and adherence history, can make a DOAC a stronger clinical choice than warfarin for a given individual.

How Prior Authorization for Eliquis Works at MDwise

Prior authorization is a formal request from your prescriber to MDwise asking the plan to cover a drug that is not automatically dispensed. The process has defined steps and timelines.

Step 1: Prescriber Submits a PA Request

Your physician, cardiologist, or hematologist completes an authorization form specifying:

• The diagnosis (e.g., nonvalvular AF with CHA2DS2-VASc score ≥2 in men or ≥3 in women, per AHA/ACC 2023 AF guidelines)
• Why warfarin is inappropriate or has failed (e.g., documented labile INR, warfarin allergy, drug interaction, patient refusal)
• Supporting labs or clinical notes

MDwise is required under Indiana Medicaid rules to respond to routine PA requests within 3 business days and to urgent requests within 24 hours. CMS 42 CFR Part 438 governs these timelines for managed-care organizations.

Step 2: MDwise Reviews Against Criteria

MDwise clinical reviewers check the request against their PA criteria, which are typically aligned with the state's PDL clinical criteria. Common approval criteria for a DOAC include:

• Confirmed diagnosis of nonvalvular AF, DVT, or PE
• Documentation of a warfarin trial with subtherapeutic or supratherapeutic INR control (time in therapeutic range <60% over at least 12 weeks is a common threshold)
• Documented contraindication to warfarin (e.g., pregnancy, specific drug-drug interaction, heparin-induced thrombocytopenia history)
• Renal function within apixaban's approved dosing range

Step 3: Approval, Denial, or Appeal

If approved, coverage is typically granted for 12 months before renewal. If denied, the prescriber and member receive a written notice with the reason. Indiana Medicaid members have the right to appeal a PA denial through:

1. An internal MDwise appeal (must be filed within 60 days of the denial notice)
2. A State Fair Hearing through the Indiana Family and Social Services Administration (FSSA), per Indiana's Medicaid appeals process

Requesting a State Fair Hearing while continuing treatment can, in some circumstances, allow continued coverage while the appeal is pending if the member files within 10 days of the denial.

Covered Alternatives to Eliquis on the MDwise Formulary

If a PA is denied, or if you and your provider decide a different agent is appropriate, MDwise covers several anticoagulants.

Warfarin (Coumadin)

Warfarin remains the backbone of Medicaid anticoagulation coverage. Generic tablets cost under $0.10 each at most pharmacies. Dosing requires regular INR monitoring, typically monthly once stable. The ACC/AHA Heart Failure and AF guidelines recommend a target INR of 2.0 to 3.0 for most AF patients. Warfarin is fully covered by MDwise with no PA for approved indications.

Rivaroxaban (Xarelto)

Rivaroxaban is another Factor Xa inhibitor with strong Phase III data. The ROCKET AF trial (N=14,264) found rivaroxaban non-inferior to warfarin for stroke prevention in AF (1.7% vs. 2.2% per year; NEJM 2011). On many state PDLs, rivaroxaban carries a similar non-preferred status to apixaban, so a PA may still be required, but some plans have negotiated preferred placement for one DOAC over another. Check your current MDwise benefit booklet or call member services at the number on your insurance card.

Dabigatran (Pradaxa)

Dabigatran is a direct thrombin inhibitor approved for nonvalvular AF. RE-LY (N=18,113) showed dabigatran 150 mg BID reduced stroke by 34% vs. Warfarin (1.11% vs. 1.69% per year; P<0.001 for superiority; NEJM 2009). Its twice-daily dosing and renal sensitivity (80% renal clearance) make it less suitable than apixaban for patients with moderate CKD, which can itself serve as a PA argument for apixaban specifically.

Low-Molecular-Weight Heparins

Enoxaparin (Lovenox) and other LMWH agents are covered for short-term bridging, VTE prophylaxis post-surgery, and in pregnancy (where DOACs are contraindicated per FDA pregnancy labeling). Long-term LMWH is generally reserved for patients with active malignancy-associated thrombosis, where the CLOT trial (N=676) showed dalteparin superior to warfarin for VTE recurrence reduction (9% vs. 17%; P=0.002; NEJM 2003).

Cost-Reduction Options If MDwise Denies or Limits Coverage

Even with a PA denial or high cost-sharing, several pathways can reduce or eliminate out-of-pocket cost for Eliquis.

Bristol-Myers Squibb / Pfizer Patient Assistance Program

The manufacturers of Eliquis operate the Eliquis 360 Support program. Patients who meet income eligibility criteria and have no other means to pay may receive Eliquis at no cost. Visit BMS's official assistance page or call 855-ELIQUIS (855-354-7847). Income limits and documentation requirements apply.

GoodRx and Pharmacy Discount Cards

GoodRx coupons can bring a 30-day supply of Eliquis (60 tablets of 5 mg) to roughly $450 to $530 at retail, which is significantly below the list price of approximately $600 to $700 per month but still expensive. These coupons cannot be used simultaneously with Medicaid coverage, so members should use them only in the narrow window between a denial and a successful appeal.

State Pharmaceutical Assistance Programs

Indiana does not currently operate a separate State Pharmaceutical Assistance Program (SPAP) for Medicaid-eligible individuals, but the NeedyMeds database maintains a searchable list of disease-specific foundations that may cover anticoagulation costs for qualifying patients.

Building a Strong PA Request: A Clinical Decision Framework

A prior authorization that clearly maps clinical evidence to patient-specific factors is far more likely to succeed than a generic request. The framework below gives prescribers a structured approach.

Document the Warfarin Trial (Or Contraindication)

The single most common PA denial reason for a DOAC is insufficient documentation of warfarin failure. Prescribers should attach:

• INR log showing time in therapeutic range (TTR) below 60% across at least 8 to 12 weeks of therapy
• Notes on warfarin drug interactions (e.g., amiodarone, fluconazole, rifampin) that destabilize INR
• Patient-reported dietary inconsistency with vitamin K intake if relevant

The SAMe-TT2R2 score, endorsed in European Heart Journal 2013, predicts which AF patients will have poor TTR on warfarin. A score of ≥2 predicts TTR <65% and directly supports DOAC use. Include this calculation in the PA.

Cite Bleeding Risk Reduction

If the patient has a prior gastrointestinal bleed, falls risk, or history of intracranial hemorrhage on warfarin, quantify it. The HAS-BLED score, described in Chest 2010, gives a numeric bleeding risk that can contextualize why lower-bleed-risk apixaban (per ARISTOTLE) is clinically appropriate. Patients with HAS-BLED ≥3 benefit most from the bleeding risk reduction that apixaban demonstrated vs. Warfarin.

Renal Function Documentation

Attach recent BMP or CMP with creatinine and eGFR. If eGFR is 30 to 50 mL/min/1.73m2, annotate why apixaban's lower renal clearance (27%) is preferable to dabigatran (80%). The KDIGO 2023 CKD guidelines support DOAC use with dose adjustment in CKD stages 3a and 3b.

Attach the Guideline Reference

Directly quote the 2023 AHA/ACC/ACCP/HRS AF Guideline: "For patients with AF and risk factors for stroke, DOACs are recommended over warfarin (Class I, Level of Evidence A), except in patients with moderate-to-severe mitral stenosis or a mechanical heart valve." Pasting this quote in the PA clinical notes forces the reviewer to acknowledge Class I guideline support.

Special Populations: When Eliquis Is Particularly Important to Secure

Certain patient groups face the greatest clinical risk if forced to use warfarin rather than apixaban. Prescribers for these patients should prepare a more detailed PA.

Older Adults With Fall Risk

Hip fracture mortality in adults over 75 is approximately 20 to 30% within 12 months, per JAMA Internal Medicine 2014. Warfarin's longer half-life and higher intracranial hemorrhage rate amplify this risk. ARISTOTLE showed apixaban cut intracranial hemorrhage by 58% vs. Warfarin (0.33% vs. 0.80% per year; P<0.001), a clinically decisive finding for this population.

Patients With Atrial Fibrillation and CKD Stage 3

For patients with both AF and eGFR 30 to 59 mL/min/1.73m2, the ARISTOTLE subgroup analysis (NEJM 2011) showed consistent benefit of apixaban vs. Warfarin across renal strata. Warfarin's narrow therapeutic index becomes harder to manage as renal function declines, increasing the clinical stakes of poor INR control.

Patients With Active Cancer-Associated Thrombosis

The CARAVAGGIO trial (N=1,170) showed apixaban non-inferior to dalteparin for recurrent VTE in cancer patients (5.6% vs. 7.9%; hazard ratio 0.63; 95% CI 0.37 to 1.07; NEJM 2020) with no significant difference in major bleeding. This data supports apixaban as a first-line option for cancer-associated thrombosis, replacing the historical preference for LMWH in this group.

How to Check Your Specific MDwise Benefit Year Coverage

Formularies change each January 1. The steps below confirm your current apixaban coverage status.

1. Log in to the MDwise member portal at mdwise.org and manage to "Pharmacy Benefits" or "Drug List."
2. Search for "apixaban" by generic name; brand names are sometimes listed separately.
3. Note the tier number, any PA requirement icon, quantity limit, or step therapy requirement.
4. Call MDwise member services (number on your ID card) to confirm whether a PA is currently on file from your prescriber.
5. Ask your pharmacist to run a "test claim" before you drop off a new prescription, which reveals in real time whether the plan will cover a fill and at what cost.

The Indiana Medicaid member handbook describes member rights in detail, including the right to a printed copy of the PDL and the right to request a PA on any drug your prescriber believes is medically necessary.